Ann: Completion of Placement, page-224

A sobering article.

Can't blame the company for the over exuberance I guess. It's the way of our current market.

And maybe it is priced about right in terms of its market cap at this point in its development. This may have been the best CR option at this time?

The key line for me, and I mentioned it in an earlier post, was the thought that they needed time just to get a version out into the market that would showcase their product. The company mentions April. In my mind, not much will happen commercially until after this.

The time delay, in this current, volatile market, will probably see the share price drift lower, with the odd bounce to keep interest level up. Just my opinion of course.

So I guess it just depends on people's belief in the tech and their investing timeframes.

'The company anticipates a launch of APAS Independence in 12 months time. Before then, a test version will be tested in a pathology laboratory to gather performance data.'

Milesy